News

HbA1c for Diabetes Diagnosis Now Mainstream


 

Disclosures: Dr. Bergenstal has held stock in Merck & Co. and participated in research or consulted for Abbott Diabetes Care, Amylin Pharmaceuticals, Bayer, Eli Lilly & Co., Intuity Medical, Lifescan (Johnson & Johnson), Mannkind, Medtronic, Merck, Novo Nordisk, ResMed, Roche Diagnostics Corp., Sanofi-Aventis, Pfizer, and Takeda Pharmaceuticals.

'Why do we follow it so closely once you're diagnosed, but pay no attention to it before you're diagnosed?'

Source DR. BERGENSTAL

Pages

Recommended Reading

News From the FDA
MDedge Internal Medicine
Mortality May Be Increased at HbA1c Below 7.5%
MDedge Internal Medicine
Partnerships Created to Develop Insulin Delivery Systems
MDedge Internal Medicine
Diabetes Pocket Guide and Booklet
MDedge Internal Medicine
Height Is Risk Factor for Diabetic Amputations
MDedge Internal Medicine
Adipose Tissue May Predict Type 2 Diabetes
MDedge Internal Medicine
Consider Bisphosphonate Holiday After 5 Years
MDedge Internal Medicine
Obese Women Underscreened for Osteoporosis
MDedge Internal Medicine
Address All Lifestyle Factors in Obese Patients
MDedge Internal Medicine
Lifestyle Intervention Reduces CRP in Diabetes
MDedge Internal Medicine